CClinicalTrials.gg
Sign In
RecruitingNCT06431477Updated May 28, 2024

Efficacy and Safety of Telmisartan Compared With Losartan

A Phase 4 interventional study of telmisartan and Losartan in Diabetic Nephropathies and Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2023, registered May 2024).
  • Started Apr 2023; still recruiting 3 years 5 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Read the detailed description

A Multi-center, Randomized, Open-label, Active comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared with Losartan in Patients with Diabetic Nephropathy and Hypertension

02

Conditions studied

  • Diabetic Nephropathies
  • Hypertension
03

In context

Kidney Diseases

3,838 studies on the registry are indexed under Kidney Diseases; 498 are open to participants now.

This study's planned enrollment of 98 is above the median of 70 across 2,639 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 293 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male of Female subjects aged ≥19 or \<75
  • Type II Diabetes Mellitus subjects who have been taken medicine
  • Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF

Exclusion criteria

Exclusion Criteria:

  • Subjects with Type I Diabetes Mellitus
  • Subjects with Primary hyper-aldosteronism
  • Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
  • Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period
  • Subjects who received other clinical trial drugs within 28 days of screening visit
  • Subjects who are unable to participate in this clinical trial at the discretion of the investigator.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Telmisartan tablet

    Drug: telmisartan

  • Active comparator
    Losartan tablet

    Drug: Losartan

Interventions

  • Drugtelmisartan

    QD, PO

  • DrugLosartan

    QD, PO

06

What researchers measure

Primary outcomes

  1. Change rate from baseline in Spot-UACR(Albumin/Creatinine Ratio)

    Time frame: 24 weeks after drug administration

07

Study locations

1 of 1 sites recruiting
  • Severance Hospital
    Seoul, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06431477
Lead sponsor
Chong Kun Dang Pharmaceutical
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Apr 19, 2023
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
May 28, 2024

Study contacts

BeomSeok Kim, M.D, Ph.D
Contact
DOCBSK@yuhs.ac
+82-2-2228-5331
BeomSeok Kim, M.D, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Kidney Diseases→

Other studies from this sponsor

Chong Kun Dang Pharmaceutical

Start the discussion